2抑制剂-话题@MedSci

#2抑制剂#

221篇内容 | 4071人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1995590, encodeId=9672199559034, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Am J Gastroenterology：环氧合酶-2抑制剂可以预防重症急性胰腺炎, objectType=article, longId=189588, objectId=ba8918958801, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba8918958801, replyNumber=0, likeNumber=0, createdTime=2020-06-27, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba8918958801, moduleTitle=Am J Gastroenterology：环氧合酶-2抑制剂可以预防重症急性胰腺炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba8918958801)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995602, encodeId=d20919956023e, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=ADA 2020：SGLT2抑制剂Farxiga降低了心力衰竭患者患糖尿病的风险, objectType=article, longId=195939, objectId=e40a195939e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e40a195939e1, replyNumber=0, likeNumber=114, createdTime=2020-10-16, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e40a195939e1, moduleTitle=ADA 2020：SGLT2抑制剂Farxiga降低了心力衰竭患者患糖尿病的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e40a195939e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995581, encodeId=e637199558168, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Lancet子刊：真实世界研究显示SGLT2抑制剂对糖尿病患者肾功能有获益, objectType=article, longId=186096, objectId=904518609696, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=904518609696, replyNumber=0, likeNumber=92, createdTime=2020-01-11, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=904518609696, moduleTitle=Lancet子刊：真实世界研究显示SGLT2抑制剂对糖尿病患者肾功能有获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=904518609696)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995595, encodeId=051419955950c, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Brit J Heamatol：他汀类药物和环氧合酶2抑制剂可提高弥漫性大B细胞淋巴瘤患者的存活率, objectType=article, longId=193101, objectId=1e4d193101ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e4d193101ba, replyNumber=0, likeNumber=106, createdTime=2021-01-04, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e4d193101ba, moduleTitle=Brit J Heamatol：他汀类药物和环氧合酶2抑制剂可提高弥漫性大B细胞淋巴瘤患者的存活率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e4d193101ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995597, encodeId=6057199559e03, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=加拿大批准BCL-2抑制剂VENCLEXTA与CD20单抗Obinutuzumab联合，用于先前未治疗的慢性淋巴细胞性白血病患者, objectType=article, longId=193606, objectId=c7931936061f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7931936061f, replyNumber=0, likeNumber=72, createdTime=2020-10-23, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7931936061f, moduleTitle=加拿大批准BCL-2抑制剂VENCLEXTA与CD20单抗Obinutuzumab联合，用于先前未治疗的慢性淋巴细胞性白血病患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7931936061f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995610, encodeId=406b1995610c7, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Lancet：SGLT2抑制剂对射血分数降低的心衰患者各类预后的影响, objectType=article, longId=200115, objectId=f8af20011537, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8af20011537, replyNumber=0, likeNumber=61, createdTime=2021-04-14, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8af20011537, moduleTitle=Lancet：SGLT2抑制剂对射血分数降低的心衰患者各类预后的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8af20011537)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995596, encodeId=70a1199559606, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=BMJ:使用SGLT2抑制剂可降低糖尿病患者严重肾功能事件风险, objectType=article, longId=193278, objectId=e2d81932e81e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e2d81932e81e, replyNumber=0, likeNumber=66, createdTime=2020-09-05, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e2d81932e81e, moduleTitle=BMJ:使用SGLT2抑制剂可降低糖尿病患者严重肾功能事件风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e2d81932e81e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995599, encodeId=41661995599fb, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Lancet：P2Y12抑制剂 vs 阿司匹林用于脉粥样硬化患者二级预防, objectType=article, longId=193805, objectId=2d31193805d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d31193805d5, replyNumber=0, likeNumber=60, createdTime=2020-09-25, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d31193805d5, moduleTitle=Lancet：P2Y12抑制剂 vs 阿司匹林用于脉粥样硬化患者二级预防, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d31193805d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995568, encodeId=ab271995568db, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=FDA批准Celgene的JAK2抑制剂Inrebic治疗骨髓纤维化, objectType=article, longId=177980, objectId=fe551e798093, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe551e798093, replyNumber=0, likeNumber=69, createdTime=2019-12-10, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe551e798093, moduleTitle=FDA批准Celgene的JAK2抑制剂Inrebic治疗骨髓纤维化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe551e798093)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995588, encodeId=24321995588a5, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Incyte的JAK1/JAK2抑制剂ruxolitinib乳膏治疗特应性皮炎的第二个III期临床成功, objectType=article, longId=188485, objectId=ddfc1884854b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ddfc1884854b, replyNumber=0, likeNumber=77, createdTime=2020-04-28, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ddfc1884854b, moduleTitle=Incyte的JAK1/JAK2抑制剂ruxolitinib乳膏治疗特应性皮炎的第二个III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ddfc1884854b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995598, encodeId=960a1995598b5, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=FDA批准阿斯利康的SGLT2抑制剂Farxiga，用于治疗射血分数降低的心力衰竭患者, objectType=article, longId=193624, objectId=acac19362471, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=acac19362471, replyNumber=0, likeNumber=76, createdTime=2021-03-30, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=acac19362471, moduleTitle=FDA批准阿斯利康的SGLT2抑制剂Farxiga，用于治疗射血分数降低的心力衰竭患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=acac19362471)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995593, encodeId=98ef199559376, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=亚盛药业的Bcl-2抑制剂APG-2575用于慢性淋巴细胞白血病或小淋巴细胞淋巴瘤的Ib/II期临床，获得NMPA的批准, objectType=article, longId=191730, objectId=1f9c191e301a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f9c191e301a, replyNumber=0, likeNumber=67, createdTime=2020-10-07, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f9c191e301a, moduleTitle=亚盛药业的Bcl-2抑制剂APG-2575用于慢性淋巴细胞白血病或小淋巴细胞淋巴瘤的Ib/II期临床，获得NMPA的批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f9c191e301a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995565, encodeId=053419955654e, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=新型第二代mTORC1 / 2抑制剂ASP7486用于治疗淋巴管畸形, objectType=article, longId=175619, objectId=ed621e56198c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed621e56198c, replyNumber=0, likeNumber=59, createdTime=2020-01-07, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed621e56198c, moduleTitle=新型第二代mTORC1 / 2抑制剂ASP7486用于治疗淋巴管畸形, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed621e56198c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995586, encodeId=c5031995586e5, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=EUR HEART J-CARD PHA：P2Y12抑制剂在急性冠脉综合征合并肾功能不全患者中的应用如何？, objectType=article, longId=187599, objectId=d44518e599f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d44518e599f3, replyNumber=0, likeNumber=66, createdTime=2020-05-19, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d44518e599f3, moduleTitle=EUR HEART J-CARD PHA：P2Y12抑制剂在急性冠脉综合征合并肾功能不全患者中的应用如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d44518e599f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995585, encodeId=9052199558552, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=EUR HEART J-CARD PHA：接受PCI治疗的心肌梗死患者接受无规划糖蛋白IIb/IIIa抑制剂的p2y12抑制剂患者的肝素抗凝程度与临床结果的关系, objectType=article, longId=187475, objectId=0c5518e475ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c5518e475ae, replyNumber=0, likeNumber=0, createdTime=2020-08-01, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c5518e475ae, moduleTitle=EUR HEART J-CARD PHA：接受PCI治疗的心肌梗死患者接受无规划糖蛋白IIb/IIIa抑制剂的p2y12抑制剂患者的肝素抗凝程度与临床结果的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c5518e475ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995589, encodeId=c72e1995589aa, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=AJG：环氧合酶-2抑制剂可以预防重症急性胰腺炎的发生, objectType=article, longId=188590, objectId=fb8c188590f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb8c188590f4, replyNumber=0, likeNumber=59, createdTime=2020-11-08, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb8c188590f4, moduleTitle=AJG：环氧合酶-2抑制剂可以预防重症急性胰腺炎的发生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb8c188590f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995570, encodeId=91e219955e09b, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=BMJ：SGLT2抑制剂可降低糖尿病患者心力衰竭风险, objectType=article, longId=178463, objectId=a7aa1e846397, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7aa1e846397, replyNumber=0, likeNumber=72, createdTime=2020-01-22, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7aa1e846397, moduleTitle=BMJ：SGLT2抑制剂可降低糖尿病患者心力衰竭风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7aa1e846397)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995580, encodeId=5f1819955801e, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=阿斯利康的心力衰竭药物SGLT2抑制剂Farxiga获得FDA优先审查, objectType=article, longId=185842, objectId=eae01858423e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eae01858423e, replyNumber=0, likeNumber=58, createdTime=2020-04-29, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eae01858423e, moduleTitle=阿斯利康的心力衰竭药物SGLT2抑制剂Farxiga获得FDA优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eae01858423e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995579, encodeId=635e19955e96d, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=慢性移植物抗宿主病的治疗：Kadmon和Meiji宣布在日本合作开发ROCK2抑制剂KD025, objectType=article, longId=185345, objectId=196018534552, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=196018534552, replyNumber=0, likeNumber=83, createdTime=2020-11-10, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=196018534552, moduleTitle=慢性移植物抗宿主病的治疗：Kadmon和Meiji宣布在日本合作开发ROCK2抑制剂KD025, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=196018534552)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995583, encodeId=83e7199558333, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Cancer Cell：HER2抑制剂联合TORC1抑制剂能够阻止癌细胞生长, objectType=article, longId=186793, objectId=2cdf186e9315, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2cdf186e9315, replyNumber=0, likeNumber=74, createdTime=2020-09-11, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2cdf186e9315, moduleTitle=Cancer Cell：HER2抑制剂联合TORC1抑制剂能够阻止癌细胞生长, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2cdf186e9315)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

2抑制剂

2020-05-29

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Am J Gastroenterology：环氧合酶-2抑制剂可以预防重症急性胰腺炎

2020-06-27

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

ADA 2020：SGLT2抑制剂Farxiga降低了心力衰竭患者患糖尿病的风险

2020-10-16

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Lancet子刊：真实世界研究显示SGLT2抑制剂对糖尿病患者肾功能有获益

2020-01-11

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Brit J Heamatol：他汀类药物和环氧合酶2抑制剂可提高弥漫性大B细胞淋巴瘤患者的存活率

2021-01-04

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

加拿大批准BCL-2抑制剂VENCLEXTA与CD20单抗Obinutuzumab联合，用于先前未治疗的慢性淋巴细胞性白血病患者

2020-10-23

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Lancet：SGLT2抑制剂对射血分数降低的心衰患者各类预后的影响

2021-04-14

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

BMJ:使用SGLT2抑制剂可降低糖尿病患者严重肾功能事件风险

2020-09-05

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Lancet：P2Y12抑制剂 vs 阿司匹林用于脉粥样硬化患者二级预防

2020-09-25

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

FDA批准Celgene的JAK2抑制剂Inrebic治疗骨髓纤维化

2019-12-10

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Incyte的JAK1/JAK2抑制剂ruxolitinib乳膏治疗特应性皮炎的第二个III期临床成功

2020-04-28

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

FDA批准阿斯利康的SGLT2抑制剂Farxiga，用于治疗射血分数降低的心力衰竭患者

2021-03-30

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

亚盛药业的Bcl-2抑制剂APG-2575用于慢性淋巴细胞白血病或小淋巴细胞淋巴瘤的Ib/II期临床，获得NMPA的批准

2020-10-07

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

新型第二代mTORC1 / 2抑制剂ASP7486用于治疗淋巴管畸形

2020-01-07

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

EUR HEART J-CARD PHA：P2Y12抑制剂在急性冠脉综合征合并肾功能不全患者中的应用如何？

2020-05-19

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

EUR HEART J-CARD PHA：接受PCI治疗的心肌梗死患者接受无规划糖蛋白IIb/IIIa抑制剂的p2y12抑制剂患者的肝素抗凝程度与临床结果的关系

2020-08-01

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

AJG：环氧合酶-2抑制剂可以预防重症急性胰腺炎的发生

2020-11-08

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

BMJ：SGLT2抑制剂可降低糖尿病患者心力衰竭风险

2020-01-22

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

阿斯利康的心力衰竭药物SGLT2抑制剂Farxiga获得FDA优先审查

2020-04-29

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

慢性移植物抗宿主病的治疗：Kadmon和Meiji宣布在日本合作开发ROCK2抑制剂KD025

2020-11-10

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Cancer Cell：HER2抑制剂联合TORC1抑制剂能够阻止癌细胞生长

2020-09-11

科室
- - 订阅+
  - 更多科室
工具
服务